Following a review of rectal spacer options, Varun Sundaram, MD, offers clinical perspectives on hyaluronic acid spacers for patients with prostate cancer undergoing radiation.
Dr. Agarwal on significance of ultra-low PSA levels achieved with apalutamide in mCSPC
January 11th 2024Neeraj Agarwal, MD, discusses an analysis from the phase 3 TITAN trial that explored the correlation between PSA response and survival among patients with metastatic castration-sensitive prostate cancer receiving apalutamide.